Leslie Silberstein, MD, HMS Professor of Pathology, Awarded 2010 Emily Cooley Memorial Award by the American Association of Blood Banks
Leslie Silberstein, MD, Harvard Medical School (HMS) Professor of Pathology (Pediatrics), was awarded the Emily Cooley Memorial Award at the 2010 American Association of Blood Banks (AABB) Annual Meeting, held in Baltimore, MD, on October 10th-12th, 2010. This award began as a lectureship in 1963 and was designated as a Memorial Award in 1983. The person who receives this award has demonstrated teaching ability and has made a major contribution to the field of immunohematology and transfusion medicine or cellular therapies. The AABB Annual Meeting Education Program Unit selects the award recipient annually with formal approval by AABB’s Board of Directors. On October 11th, 2010, Dr. Silberstein was honored with the Emily Cooley Memorial Award and presented a lecture entitled “Translation of Cell Based-Therapies”, illustrating the therapeutic use of specific hematopoietic cell populations for immunotherapy of cancer and infectious diseases, gene therapy for immunodeficiency disorders and stem cell therapy for diseased or damaged tissues. Dr. Silberstein is the Director of the Joint Program in Transfusion Medicine at Children's Hospital Boston, Brigham and Women's Hospital, and the Dana-Farber Cancer Institute. Dr. Silberstein also is the Director of the Center for Human Cell Therapy Boston (CHCT Boston) at the Immune Disease Institute/Programs in Cellular and Molecular Medicine at Children’s Hospital Boston.
CHCT Boston Awarded 5 year Production Assistance for Cellular Therapy (PACT) contract by the National Heart, Lung and Blood Institute (NHLBI) to advance cell therapy research
On January 15th 2010, Dr. Leslie E. Silberstein of the Center for Human Cell Therapy Boston (CHCT) at the Immune Disease Institute was awarded a Production Assistance for Cellular Therapies contract (PACT) by the National Institute of Health. CHCT Boston was created in 2004 to promote the development of novel cellular therapies. CHCT Boston is led by its Director, Dr. Leslie Silberstein (Joint Program in Transfusion Medicine at Children's Hospital Boston, Brigham and Women's Hospital, and the Dana-Farber Cancer Institute) and Dr. Jerome Ritz (Dana-Farber Cancer Institute).
The intent of this competitive award is to advance cellular therapy research in broad areas, including immunotherapy for cancer/infectious disease and stem cell therapy for congenital and acquired disorders. The 5-year program, funded in the amount of $14.5 million will be a cross-institutional effort including all major Harvard Medical School affiliated institutions as well as the Harvard Stem Cell Institute.
CHCT Boston will join 4 cell processing facilities nationwide. As a member of the PACT Group, CHCT Boston, comprised of the Translational Laboratory (Trans Lab) and the Connell O’Reilly Cell Manipulation Core Facility (CMCF) of the Dana Farber Cancer Institute, will partner with the PACT Steering Committee to identify basic laboratory investigators who have developed successful cell-based therapies in pre-clinical model systems and support the transition of these new approaches to the stage of clinical evaluation in patients. In addition to supporting investigators in translational research, the PACT Group also will offer educational resources for the cell therapy research community. PACT will begin accepting new applications starting March 1st, 2010. For additional information on PACT application guidelines please visit www.pactgroup.net or contact Darah Tappitake, Administrative Manager, CHCT Boston, at tappitake@idi.harvard.edu.
The intent of this competitive award is to advance cellular therapy research in broad areas, including immunotherapy for cancer/infectious disease and stem cell therapy for congenital and acquired disorders. The 5-year program, funded in the amount of $14.5 million will be a cross-institutional effort including all major Harvard Medical School affiliated institutions as well as the Harvard Stem Cell Institute.
CHCT Boston will join 4 cell processing facilities nationwide. As a member of the PACT Group, CHCT Boston, comprised of the Translational Laboratory (Trans Lab) and the Connell O’Reilly Cell Manipulation Core Facility (CMCF) of the Dana Farber Cancer Institute, will partner with the PACT Steering Committee to identify basic laboratory investigators who have developed successful cell-based therapies in pre-clinical model systems and support the transition of these new approaches to the stage of clinical evaluation in patients. In addition to supporting investigators in translational research, the PACT Group also will offer educational resources for the cell therapy research community. PACT will begin accepting new applications starting March 1st, 2010. For additional information on PACT application guidelines please visit www.pactgroup.net or contact Darah Tappitake, Administrative Manager, CHCT Boston, at tappitake@idi.harvard.edu.
Center for Human Cell Therapy
Karp Family Research Building
One Blackfan Circle
Boston, MA, 02115
www.chct.org
copyright 2005 Center for Human Cell Therapy. All rights reserved
Karp Family Research Building
One Blackfan Circle
Boston, MA, 02115
www.chct.org
copyright 2005 Center for Human Cell Therapy. All rights reserved
